Patient centricity, a key priority for today´s pharmaceutical industry, extends also to the B2B partners. The profound shift of meeting the expectations of ever better informed and more involved patients and care givers also concerns B2B business partners of the pharmaceutical industry. Patient centricity presents challenges as well as ample opportunities for value generation for B2B partners along the pharmaceutical value chain.

Following the approach of simply listening to and observing patients in their use of transdermal therapeutic systems (TTS), LTS has ventured into the previously unknown. Namely, how do patients actually use and perceive transdermal delivery systems TTS?

Applying state of the art consumer research in a patient study in Germany, LTS has systematically assessed patient requirements and appreciation of transdermal delivery systems vs. conventional administration routes. Interviewing patients directly, LTS gained valuable insights. The results of the LTS sponsored patient study confirmed the decisive patient preference for transdermal delivery in pain indications over alternative forms of administration. Furthermore, the patient feedback provided valuable insights of how to further improve the patient´s experience. Next to clinical and therapeutic considerations, the patient´s feedback when using TTS guides the way how to further optimize advantageous delivery systems. Corresponding with improved patient experience also value generation and retention for the pharmaceutical industry stands to benefit.

Background of the study: 50 patients suffering from chronic moderate to severe pain and using (fentanyl, buprenorphine or lidocaine) TTS over a period of minimum 5 month were interviewed by an independent market research institute (Institut IMIG, Munich).